Prediction of Anti-cancer Nanotherapy Efficacy by Imaging
نویسندگان
چکیده
منابع مشابه
Prediction of Anti-cancer Nanotherapy Efficacy by Imaging
Anticancer nanotherapeutics have shown mixed results in clinical trials, raising the questions of whether imaging should be used to i) identify patients with a higher likelihood of nanoparticle accumulation, ii) assess nanotherapeutic efficacy before traditional measures show response, and iii) guide adjuvant treatments to enhance therapeutic nanoparticle (TNP) delivery. Here we review the use ...
متن کاملNanoreporter PET predicts the efficacy of anti-cancer nanotherapy
The application of nanoparticle drug formulations, such as nanoliposomal doxorubicin (Doxil), is increasingly integrated in clinical cancer care. Despite nanomedicine's remarkable potential and growth over the last three decades, its clinical benefits for cancer patients vary. Here we report a non-invasive quantitative positron emission tomography (PET) nanoreporter technology that is predictiv...
متن کاملCell-Based Targeting of Anti-Cancer Nanotherapy to Tumors
Volume 5(4) 142-143 (2013) 142 J Cancer Sci Ther ISSN:1948-5956 JCST, an open access journal There is emerging and convincing data that certain cells, administered systemically, have a natural propensity to migrate to cancerous tissues in preclinical models. Examples of such cells include neural stem cells [1], bone marrow mesenchymal stem cells [2], umbilical cord Wharton’s jelly stem cells [3...
متن کاملIn vitro prediction of the efficacy of molecularly targeted cancer therapy by Raman spectral imaging
Mutational acquired resistance is a major challenge in cancer therapy. Somatic tumours harbouring some oncogenic mutations are characterised by a high mortality rate. Surprisingly, preclinical evaluation methods do not show clearly resistance of mutated cancers to some drugs. Here, we implemented Raman spectral imaging to investigate the oncogenic mutation resistance to epidermal growth factor ...
متن کاملA Two-Step Pretargeted Nanotherapy for CD20 Crosslinking May Achieve Superior Anti-Lymphoma Efficacy to Rituximab
The use of rituximab, an anti-CD20 mAb, in combination with chemotherapy is the current standard for the treatment of B-cell lymphomas. However, because of a significant number of treatment failures, there is a demand for new, improved therapeutics. Here, we designed a nanomedicine that crosslinks CD20 and directly induces apoptosis of B-cells without the need for toxins or immune effector func...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nanotheranostics
سال: 2017
ISSN: 2206-7418
DOI: 10.7150/ntno.20564